var data={"title":"Acquired pure red cell aplasia in the adult","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acquired pure red cell aplasia in the adult</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/contributors\" class=\"contributor contributor_credentials\">Stanley L Schrier, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/contributors\" class=\"contributor contributor_credentials\">William C Mentzer, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 01, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acquired pure red cell aplasia (PRCA) is a rare, generally chronic condition of profound anemia characterized by a severe reduction in the number of reticulocytes in the peripheral blood and the virtual absence of erythroid precursors in the bone marrow. All other cell lineages are present and appear morphologically normal.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A similar but usually self-limited condition seen during the first years of life, transient erythroblastopenia of childhood, is discussed separately. (See <a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production#H11\" class=\"medical medical_review\">&quot;Anemia in children due to decreased red blood cell production&quot;, section on 'Transient erythroblastopenia of childhood (TEC)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A congenital form of red cell aplasia is known as Diamond-Blackfan anemia (DBA). DBA is associated with a number of congenital abnormalities, risk of malignancy, and marked unresponsiveness to <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>. (See <a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production#H3\" class=\"medical medical_review\">&quot;Anemia in children due to decreased red blood cell production&quot;, section on 'Diamond-Blackfan anemia'</a>.)</p><p/><p>Acquired PRCA will be discussed here. Acquired PRCA due to the presence of anti-erythropoietin antibodies secondary to treatment with recombinant human erythropoietin is discussed separately. (See <a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies\" class=\"medical medical_review\">&quot;Pure red cell aplasia due to anti-erythropoietin antibodies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Associated disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acquired pure red cell aplasia (PRCA) in the adult is most often idiopathic, although a number of underlying causes can exist (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Large granular lymphocyte leukemia</strong> &mdash; In a Mayo Clinic series of 47 adults with acquired pure red blood cell aplasia, large granular lymphocyte (LGL) leukemia was the most common underlying cause [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-large-granular-lymphocyte-leukemia#H458740684\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Myelodysplastic syndrome</strong> &mdash; In 4 to 20 percent of idiopathic cases, PRCA represents the prodrome to a myelodysplastic syndrome (MDS) [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,3,4\" class=\"abstract_t\">1,3,4</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-myelodysplastic-syndromes#H5\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the myelodysplastic syndromes&quot;, section on 'Clinical presentation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Thymoma</strong> &mdash; A thymoma is present in approximately 5 percent of patients with PRCA [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,5\" class=\"abstract_t\">1,5</a>].</p><p/><p class=\"bulletIndent1\">A number of cases of coexisting myasthenia gravis and PRCA have been described in the literature; all were thymoma-associated except for one with thymic hyperplasia [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>ABO-incompatible hematopoietic cell transplantation</strong> &mdash; PRCA may complicate ABO-incompatible hematopoietic cell transplantation. (See <a href=\"topic.htm?path=donor-selection-for-hematopoietic-cell-transplantation#H91588735\" class=\"medical medical_review\">&quot;Donor selection for hematopoietic cell transplantation&quot;, section on 'ABO and Rh status'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anti-erythropoietin antibodies </strong>&mdash; Acquired PRCA may occur due to the presence of anti-erythropoietin antibodies secondary to treatment with recombinant human erythropoietin. While most of these reports were in patients with chronic kidney disease, this complication has also been seen in patients with hepatitis C receiving antiviral therapy (eg, <a href=\"topic.htm?path=ribavirin-drug-information\" class=\"drug drug_general\">ribavirin</a>, interferon) along with an erythropoiesis-stimulating agent [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies\" class=\"medical medical_review\">&quot;Pure red cell aplasia due to anti-erythropoietin antibodies&quot;</a> and <a href=\"topic.htm?path=management-of-the-side-effects-of-peginterferon-and-ribavirin-used-for-treatment-of-chronic-hepatitis-c-virus-infection#H4\" class=\"medical medical_review\">&quot;Management of the side effects of peginterferon and ribavirin used for treatment of chronic hepatitis C virus infection&quot;, section on 'Use of erythropoietic growth factors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lymphoproliferative disorders</strong> &mdash; PRCA has been described in a number of T cell and B cell lymphoproliferative disorders. As an example, in chronic lymphocytic leukemia, as many as 6 percent of patients have PRCA when tested for presence of this disorder. (See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemia#H602942881\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia&quot;, section on 'Laboratory abnormalities'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Plasma cell disorders</strong> &mdash; PRCA has been described in patients with monoclonal gammopathies that were not clinically apparent. In a series of 51 individuals with PRCA who were evaluated with serum and urine protein electrophoresis and review of their bone marrow samples using immunohistochemical staining for plasma cells, 12 (24 percent) were identified as having monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/8\" class=\"abstract_t\">8</a>]. Three of these individuals had a response to anti-myeloma therapy with transfusion independence. (See <a href=\"topic.htm?path=clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">&quot;Clinical course and management of monoclonal gammopathy of undetermined significance&quot;</a> and <a href=\"topic.htm?path=smoldering-multiple-myeloma\" class=\"medical medical_review\">&quot;Smoldering multiple myeloma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drugs</strong> &mdash; Certain drugs (eg, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a>, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, valproic acid, <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil) have been associated with PRCA (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,9,10\" class=\"abstract_t\">1,9,10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Parvovirus B19 infection</strong> &mdash; The B19 parvovirus is a cause of PRCA [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/11-13\" class=\"abstract_t\">11-13</a>]. The parvovirus is thought to directly attack and destroy proerythroblasts by attaching to the blood group P antigen (globoside) receptor [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/14,15\" class=\"abstract_t\">14,15</a>]; cytotoxic antibodies are not found, nor is there evidence of T-cell-mediated immunosuppression [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/11\" class=\"abstract_t\">11</a>]. Severe anemia is most likely to occur in individuals with underlying hemolytic anemia (eg, sickle cell disease, hereditary spherocytosis) or general immunocompromise (HIV infection). (See <a href=\"topic.htm?path=treatment-and-prevention-of-parvovirus-b19-infection\" class=\"medical medical_review\">&quot;Treatment and prevention of parvovirus B19 infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\">The aplasia associated with B19 parvovirus often produces a characteristic morphologic finding: the presence of giant proerythroblasts in the bone marrow (<a href=\"image.htm?imageKey=HEME%2F51435\" class=\"graphic graphic_picture graphicRef51435 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Recent exposure to the virus is confirmed by the presence of anti-B19 IgM antibodies in the serum [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/12\" class=\"abstract_t\">12</a>]. The diagnosis can also be established by the presence of B19 DNA. In one retrospective study, for example, B19 DNA was found in the serum of 8 of 57 patients (14 percent) with PRCA [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-parvovirus-b19-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of parvovirus B19 infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Viral infection</strong> &mdash; Transient episodes of red cell aplasia have been described following a number of other viral illnesses, such as hepatitis A, hepatitis C virus (HCV), human immunodeficiency virus (HIV), <span class=\"nowrap\">HIV/HCV</span> coinfection, EBV, and cytomegalovirus, but often are not recognized clinically [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/16-19\" class=\"abstract_t\">16-19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autoimmune disorders</strong> &mdash; PRCA has been described in patients with autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. (See <a href=\"topic.htm?path=hematologic-manifestations-of-rheumatoid-arthritis#H8\" class=\"medical medical_review\">&quot;Hematologic manifestations of rheumatoid arthritis&quot;, section on 'Pure red cell aplasia'</a>.)</p><p/><p class=\"bulletIndent1\">In some of these patients, their serum and its IgG fraction inhibit the growth of patient and normal erythroid progenitors. As an example, a growing number of cases of neutralizing antibodies to exogenous recombinant EPO, causing pure red cell aplasia and refractory anemia in hemodialysis patients, have been described. In other patients, there is no serum inhibitory activity and the suppression seems to be mediated by T lymphocytes [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Erythroid-specific suppression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The multipotent hematopoietic stem cell is not the target of attack in PRCA. Lymphopoiesis, granulopoiesis, and megakaryocytopoiesis are all normal. (See <a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">&quot;Overview of hematopoietic stem cells&quot;</a>.)</p><p>When bone marrow from patients with PRCA is grown in semisolid media, the committed erythroid progenitor cells Burst Forming Unit erythroid (BFUe) and Colony Forming Unit erythroid (CFUe) are present even though the marrow is devoid of erythroid precursors [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=regulation-of-erythropoiesis#H2\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;, section on 'Erythroid progenitor cells'</a>.)</p><p>The first morphologically identifiable erythroid precursor in normal marrow is the proerythroblast, which is absent in the bone marrow in PRCA. Thus, the site of suppression is usually at the stage between CFUe and the proerythroblast, although arrest between BFUe and CFUe has been demonstrated in a few cases [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1\" class=\"abstract_t\">1</a>]. Very rarely, BFUe are also decreased [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=regulation-of-erythropoiesis#H3\" class=\"medical medical_review\">&quot;Regulation of erythropoiesis&quot;, section on 'Precursors and mature cells'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Mediators of suppression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In approximately 60 percent of patients with PRCA, their serum and its IgG fraction inhibits the growth of patient and normal erythroid progenitors in vitro [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,20\" class=\"abstract_t\">1,20</a>]. The target antigen is usually not known; in a few cases, however, the IgG fraction contains an inhibitor of erythropoietin. (See <a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies#H10\" class=\"medical medical_review\">&quot;Pure red cell aplasia due to anti-erythropoietin antibodies&quot;, section on 'Anti-EPO antibodies'</a>.)</p><p>In other cases of autoimmune PRCA, suppression of erythropoiesis seems to be mediated by T lymphocytes [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,2\" class=\"abstract_t\">1,2</a>]. A subset of T lymphocytes has been implicated and clonal changes may be seen [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1\" class=\"abstract_t\">1</a>]. One study evaluated 14 of 47 patients with PRCA for T cell receptor gene rearrangements: clonal rearrangement was noted in nine [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"abstract_t\">2</a>]. Clonal abnormalities were also identified by karyotypic studies in 4 of 28 patients. (See <a href=\"topic.htm?path=treatment-of-large-granular-lymphocyte-leukemia\" class=\"medical medical_review\">&quot;Treatment of large granular lymphocyte leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">PRESENTATION</span></p><p class=\"headingAnchor\" id=\"H280339\"><span class=\"h2\">Onset of anemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The net result of the immune attack in PRCA is a marked reduction or absence of all recognizable red cell precursors in the bone marrow and absence of reticulocytes in the peripheral blood. Therefore the anemia is due solely to the complete or nearly complete cessation of red cell production.</p><p>Since red cells normally survive for approximately 120 days in the circulation, anemia develops at a rate of 0.8 percent per day (ie, <span class=\"nowrap\">1/120</span> of the circulating red cells die each day but are not replaced). This pace is slow enough to allow the body to compensate for a reduced oxygen-carrying capacity. Accordingly, the patient with PRCA may not present until a significant degree of anemia is present, often to a hematocrit &lt;10 percent, a point at which these compensatory changes are no longer sufficient. (See <a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult#H2\" class=\"medical medical_review\">&quot;Indications and hemoglobin thresholds for red blood cell transfusion in the adult&quot;, section on 'Role of blood in oxygen delivery'</a>.)</p><p class=\"headingAnchor\" id=\"H6631632\"><span class=\"h2\">Clinical findings</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As the onset of anemia in PRCA is insidious, patients may have little in the way of signs and symptoms until the anemia becomes severe. Extreme pallor or decreased exercise tolerance may be the first signs of this disorder in a previously healthy individual.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No physical findings will be present unless there is an associated or underlying disorder (eg, chronic lymphocytic leukemia, rheumatoid arthritis).</p><p/><p class=\"headingAnchor\" id=\"H6631639\"><span class=\"h2\">Laboratory findings</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anemia is often severe and is normocytic and normochromic. Spherocytes, red cell fragments, macrocytes, and polychromatophilic red cells are not seen on routine peripheral blood smears. An exception is parvovirus-associated transient suppression of erythropoiesis seen in chronic hemolytic anemia, in which cells typical of the underlying anemia (eg, spherocytes in the case of hereditary spherocytosis) are evident on the smear. Reticulocytes are markedly decreased and are often absent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no changes in white blood cell or platelet counts; abnormal circulating white blood cells are not present in idiopathic cases, but may be seen in patients with an underlying hematologic disorder (eg, chronic lymphocytic leukemia, large granular lymphocyte leukemia).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As ineffective erythropoiesis and hemolytic anemia are not seen in PRCA, levels of indirect bilirubin, haptoglobin, and lactate dehydrogenase are normal, and the direct antiglobulin (Coombs) test is negative.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once the bone marrow stops making red cells, the transfer of iron from plasma to the bone marrow also ceases, resulting in an increase in serum iron concentration, often to the level of the total iron binding capacity, such that transferrin saturation approaches 100 percent and the unsaturated iron binding capacity approaches zero.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone marrow examination shows normal overall cellularity, with complete or virtually complete absence of red cell precursors. In patients with PRCA due to parvovirus infection, characteristic giant proerythroblasts can be seen (<a href=\"image.htm?imageKey=HEME%2F51435\" class=\"graphic graphic_picture graphicRef51435 \">picture 1</a>).</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In all cases of PRCA, a search should be made for an underlying condition, including certain drugs, thymoma, hypoplastic myelodysplastic syndrome, large granular lymphocyte (LGL) leukemia, and viral infection (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>) (see <a href=\"#H17\" class=\"local\">'Presentation'</a> above). Appropriate <strong>initial</strong> studies for such patients include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count, examination of the peripheral smear, reticulocyte count</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Routine tests of hepatic and renal function</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CT or MRI of the chest to rule out thymoma and other neoplasms</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral studies as appropriate, including parvovirus</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bone marrow aspiration and biopsy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">Autoimmune/antinuclear</span> antibody studies as appropriate</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Specialized tests (when an underlying hematologic condition is suspected) may include karyotype, T cell receptor clonality studies, peripheral blood immunophenotyping (see <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-large-granular-lymphocyte-leukemia#H458740768\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia&quot;, section on 'Immunophenotype'</a>)</p><p/><p>The diagnosis of PRCA is established when <strong>all</strong> of the following are present:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normocytic, normochromic anemia; rarely, macrocytic</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A very low (or zero) reticulocyte percentage, and an absolute reticulocyte count <span class=\"nowrap\">&lt;10,000/microL</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal white blood cell and platelet counts</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A normocellular bone marrow that shows normal myelopoiesis, lymphopoiesis, and megakaryocytopoiesis, but few if any erythroid precursors.</p><p/><p class=\"headingAnchor\" id=\"H2568967\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If an adult fulfills all of the diagnostic criteria for PRCA as enumerated above, the differential diagnosis is limited to the occasional patient with severe autoimmune hemolytic anemia in whom the bone marrow erythropoietic response has been transiently suppressed. Such patients present with severe hemolytic anemia (eg, increased lactate dehydrogenase and indirect bilirubin, decreased haptoglobin), spherocytic red cells, and a positive direct antiglobulin (Coombs) test. (See <a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult#H2782676094\" class=\"medical medical_review\">&quot;Diagnosis of hemolytic anemia in the adult&quot;, section on 'Hemolysis without reticulocytosis'</a>.)</p><p>The differential diagnosis of severe reticulocytopenia in children includes a number of etiologies in addition to those enumerated above (eg, transient erythroblastopenia of childhood, Diamond-Blackfan anemia). These disorders are discussed in depth elsewhere (see <a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production\" class=\"medical medical_review\">&quot;Anemia in children due to decreased red blood cell production&quot;</a>).</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In one of the largest available series, 5 of 37 patients (14 percent) with PRCA had spontaneously-remitting disease (eg, pregnancy, some cases of parvovirus infection, drugs), requiring no specific therapy other than transfusion for symptomatic anemia and cessation of possible offending drugs [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21-23\" class=\"abstract_t\">21-23</a>].</p><p>For the remaining patients, acquired pure red cell aplasia is most often a chronic condition. Although remissions can be attained with the use of immunosuppressive or cytotoxic agents, there is a high propensity for relapse following discontinuation of treatment. Relapse-free survivals (ie, survival without the need for red cell transfusion) can be as short as three months or longer than eight years, depending upon the treatment program employed and whether or not maintenance treatment is given [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study reported in 1984, overall survival in patients with idiopathic PRCA was &gt;10 years, whereas it was four years in those with PRCA secondary to another condition (eg, leukemia, lymphoma) [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21\" class=\"abstract_t\">21</a>]. Infection was the most common cause of morbidity and mortality, likely due to the side effects of treatment with agents such as glucocorticoids and <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 2007 report in 62 patients with primary (idiopathic) PRCA indicated a 10-year overall survival of 95 percent, with no significant difference between those treated with <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> or those treated with glucocorticoids [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/25\" class=\"abstract_t\">25</a>]. In a separate 2008 report on 41 patients with thymoma and PRCA, median overall survival was 12 years [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no standard treatment for PRCA, either for initial treatment or for relapsed disease. Further, there are no prospective randomized trials comparing transfusion alone to any of the available regimens and none comparing one regimen to another.</p><p class=\"headingAnchor\" id=\"H6631738\"><span class=\"h2\">Initial management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial management of PRCA includes all of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Red cell transfusions for symptomatic anemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cessation of possible offending drugs (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Search for an associated condition</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immediate hematologic consultation</p><p/><p>In one of the largest available series, 5 of 37 patients (14 percent) with PRCA had spontaneously-remitting disease (eg, pregnancy, some cases of parvovirus infection, drugs), requiring no specific therapy other than the above [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21-23\" class=\"abstract_t\">21-23</a>].</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Presence of associated conditions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of conditions may be associated with PRCA. Management of these conditions is individualized, as discussed below (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>ABO-incompatible hematopoietic cell transplantation</strong> &mdash; PRCA that occurs following ABO incompatible hematopoietic cell transplantation is usually a self-limited complication. (See <a href=\"topic.htm?path=donor-selection-for-hematopoietic-cell-transplantation#H91588735\" class=\"medical medical_review\">&quot;Donor selection for hematopoietic cell transplantation&quot;, section on 'ABO and Rh status'</a>.) Occasional cases may have a delayed onset, prolonged course, and poor response to treatment. Anecdotal reports have described responses to plasma exchange, immunoadsorption columns, reduction in the dose of immunosuppressive agents, donor lymphocyte infusion, steroids, erythropoietin, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, and intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/27-34\" class=\"abstract_t\">27-34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Thymoma</strong> &mdash; There is a well-documented association of PRCA with thymoma, with an incidence of about 5 percent [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21\" class=\"abstract_t\">21</a>]. Even if a thymoma is present, surgical resection only occasionally results in improvement or cure of the PRCA, and additional treatment (eg, glucocorticoids, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>), is needed in most cases [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1,5,35,36\" class=\"abstract_t\">1,5,35,36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Parvovirus infection</strong> &mdash; The usual course of parvovirus associated-anemia is spontaneous resolution within two to three weeks. If spontaneous improvement does not occur during this time, the patient may be an immunocompromised host. Intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) contains antibodies to parvovirus. A single infusion of 400 <span class=\"nowrap\">mg/kg</span> of IVIG given over two to three hours may be effective in this setting [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/37,38\" class=\"abstract_t\">37,38</a>]. Discussions of this infection in patients with malignancy and anemia can be found elsewhere. (See <a href=\"topic.htm?path=treatment-and-prevention-of-parvovirus-b19-infection#H7\" class=\"medical medical_review\">&quot;Treatment and prevention of parvovirus B19 infection&quot;, section on 'Chronic infection with anemia'</a> and <a href=\"topic.htm?path=hematologic-complications-of-malignancy-anemia-and-bleeding#H17\" class=\"medical medical_review\">&quot;Hematologic complications of malignancy: Anemia and bleeding&quot;, section on 'Parvovirus B19 infection'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anti-erythropoietin antibodies</strong> &mdash; Management of patients with acquired pure red cell aplasia secondary to treatment with recombinant human erythropoietin (EPO) is discussed separately [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/39\" class=\"abstract_t\">39</a>]. (See <a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies\" class=\"medical medical_review\">&quot;Pure red cell aplasia due to anti-erythropoietin antibodies&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H27\"><span class=\"h2\">Presence of immune-mediated disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of PRCA with no other associated disorder (ie, idiopathic PRCA) <span class=\"nowrap\">and/or</span> which has not remitted spontaneously following a short period of observation is based upon the supposition that the attack is immune mediated and therefore might respond to immunosuppressive therapy. Response to such treatment is characterized by a brisk reticulocytosis followed by an increase in hemoglobin concentration and a decreased need for red cell transfusions.</p><p>Several different regimens have been used for the initial treatment of PRCA. The most commonly employed regimens include glucocorticoids, glucocorticoids plus <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, and glucocorticoids plus <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>. These regimens are largely empiric since there are no randomized clinical trials comparing the various therapeutic alternatives for this uncommon condition. Regimen selection is dependent upon an assessment of their short-term and long-term toxicities, need for hospitalization and drug monitoring, underlying disorder(s), and cost. Non-randomized studies suggest that those with an underlying T cell large granular lymphocyte leukemia respond better to cyclophosphamide-based regimens [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/40\" class=\"abstract_t\">40</a>], while those with an underlying B cell lymphoma may respond better to a rituximab-containing regimen [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/41-43\" class=\"abstract_t\">41-43</a>]. (See <a href=\"topic.htm?path=treatment-of-large-granular-lymphocyte-leukemia#H35829049\" class=\"medical medical_review\">&quot;Treatment of large granular lymphocyte leukemia&quot;, section on 'Cyclophosphamide'</a>.)</p><p class=\"headingAnchor\" id=\"H6632060\"><span class=\"h3\">Initial treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment should be initiated with glucocorticoids (eg, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> at an oral dose of 60 <span class=\"nowrap\">mg/day</span> in divided doses). In one retrospective study, 9 of 25 patients (36 percent) responded in one to three months to this treatment [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"abstract_t\">2</a>], while overall response rates to the use of glucocorticoids alone have been in the range of 30 to 62 percent [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/24,25\" class=\"abstract_t\">24,25</a>]. However, most patients treated with this medication relapse during tapering of therapy.</p><p class=\"headingAnchor\" id=\"H6632067\"><span class=\"h4\">Addition of cyclosporine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If no response to glucocorticoids occurs after one to two months, as measured by the absence of an increase in reticulocytes and hemoglobin, we and others prefer to treat patients with a trial of oral <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, since response rates to this agent in the available literature for idiopathic PRCA are better than those following treatment with alkylating agents, such as <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/25,44\" class=\"abstract_t\">25,44</a>].</p><p>Doses of <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> employed for the treatment of acquired pure red cell aplasia have varied widely, from 200 to 600 <span class=\"nowrap\">mg/day</span> and from 2.9 to 12 <span class=\"nowrap\">mg/kg/day,</span> with no overall agreement [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2,24,45\" class=\"abstract_t\">2,24,45</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We prefer a starting dose of 5 <span class=\"nowrap\">mg/kg/day</span> (not more than 10 <span class=\"nowrap\">mg/kg</span> per day) divided into two equal doses, with subsequent dose adjustment, aiming for a trough <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> level of 200 <span class=\"nowrap\">ng/mL</span> at six hours following drug ingestion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Doses of 10 to 12 <span class=\"nowrap\">mg/kg</span> per day have been toxic for Japanese patients, who have responded to lower doses, in the range of 2.9 to 7.6 <span class=\"nowrap\">mg/kg</span> per day (mean &plusmn; SD of 4.8 &plusmn; 1.2 <span class=\"nowrap\">mg/kg</span> per day) [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/24,25\" class=\"abstract_t\">24,25</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Of interest, suggested starting doses of <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> for the treatment of aplastic anemia are also in the range of 10 to 12 <span class=\"nowrap\">mg/kg</span> per day, although this usually requires reduction in dosing to 5 to 7 <span class=\"nowrap\">mg/kg/day,</span> more in line with the Japanese experience. (See <a href=\"topic.htm?path=treatment-of-aplastic-anemia-in-adults#H1357908\" class=\"medical medical_review\">&quot;Treatment of aplastic anemia in adults&quot;, section on 'Eltrombopag, horse ATG, CsA, and prednisone'</a>.)</p><p/><p><a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">Cyclosporine</a> is reported to produce a response in 65 to 87 percent of otherwise refractory patients [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/24,25,45\" class=\"abstract_t\">24,25,45</a>]. It should be continued for approximately three months if there is a response; slow tapering is then instituted as relapse is common when this medication is discontinued [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"abstract_t\">2</a>]. In one report, relapse was noted within three months in 12 of 14 patients (86 percent) in whom cyclosporine was discontinued, while relapse was noted in only 3 of 27 patients (11 percent) given cyclosporine-containing maintenance therapy [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H6632074\"><span class=\"h4\">Addition of cyclophosphamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If no response occurs after two to three months of treatment with glucocorticoids, and <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> use is contraindicated or not tolerated, an alternative treatment program is to add <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> at an oral dose of 2 to 3 <span class=\"nowrap\">mg/kg</span> per day [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"abstract_t\">2</a>]. Our practice is to taper <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> rapidly in this setting to avoid its well-known complications.</p><p>In one report, 8 of 15 patients (53 percent) with LGL leukemia and PRCA responded to <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> in one to three months [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"abstract_t\">2</a>]. Similar response rates to the use of glucocorticoids in combination with cytotoxic drugs were noted in 18 of 32 patients (56 percent) with idiopathic PRCA [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21\" class=\"abstract_t\">21</a>]. If a response is achieved, we empirically taper cyclophosphamide slowly over two to three months.</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h3\">Relapsed and resistant disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The overall long-term response and relapse rates following immunosuppression in PRCA are not known. One report suggested that the relapse rate may be as high as 80 percent at 24 months after achieving an initial response [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1\" class=\"abstract_t\">1</a>], while a second report indicated relapse in 13 of 23 patients (57 percent) whose remissions were induced by cytotoxic agents in combination with glucocorticoids [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with resistant PRCA may respond to a single course of intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG, 400 <span class=\"nowrap\">mg/kg</span> given daily for five days), while others have responded to a single dose [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/46\" class=\"abstract_t\">46</a>]. There are no data upon which one can base a choice of IVIG as primary or third or fourth line therapy. We occasionally begin therapy with IVIG if the anemia is symptomatic and a rapid response is clinically desirable. In the United States, financial issues may constrain this approach, since IVIG is expensive and is not approved by the FDA for this indication.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other drugs that have been used in refractory cases include <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> (2 to 3 <span class=\"nowrap\">mg/kg</span> per day), antilymphocyte globulin, antithymocyte globulin, the anti-CD20 monoclonal antibody <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, the monoclonal anti-CD52 antibody <a href=\"topic.htm?path=alemtuzumab-drug-information\" class=\"drug drug_general\">alemtuzumab</a>, and the monoclonal anti-interleukin 2 receptor antibody <a href=\"topic.htm?path=daclizumab-withdrawn-from-market-drug-information\" class=\"drug drug_general\">daclizumab</a> [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/41,47-57\" class=\"abstract_t\">41,47-57</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hematopoietic cell transplantation may be effective in selected patients with refractory disease [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/58\" class=\"abstract_t\">58</a>]. (See <a href=\"topic.htm?path=treatment-of-aplastic-anemia-in-adults\" class=\"medical medical_review\">&quot;Treatment of aplastic anemia in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A patient with inoperable thymoma and red cell aplasia responded well to a combination of the somatostatin analogue <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> and <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/59\" class=\"abstract_t\">59</a>]. The general applicability of this approach has since been confirmed [<a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/60,61\" class=\"abstract_t\">60,61</a>]. (See <a href=\"topic.htm?path=clinical-presentation-and-management-of-thymoma-and-thymic-carcinoma#H1626413\" class=\"medical medical_review\">&quot;Clinical presentation and management of thymoma and thymic carcinoma&quot;, section on 'Management'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H30\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Associated conditions</strong> &mdash; While the majority of patients with pure red cell aplasia (PRCA) have no associated condition (ie, acquired idiopathic PRCA), some will have PRCA in association with another disorder. The major associated conditions to be considered include certain drugs, thymoma, hypoplastic myelodysplastic syndrome, large granular lymphocyte (LGL) leukemia, and parvovirus infection (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>). (See <a href=\"#H17\" class=\"local\">'Presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diagnosis</strong> &mdash; The diagnosis of PRCA is suspected in a patient with anemia and a very low (or zero) reticulocyte percentage. PRCA is confirmed when all of the following are present: normocytic normochromic anemia, low or zero reticulocyte percentage, absolute reticulocyte count <span class=\"nowrap\">&lt;10,000/microL,</span> normal white blood cell and platelet counts, and a normocellular bone marrow that shows normal myelopoiesis and megakaryocytopoiesis, but few if any erythroid precursors. Appropriate initial studies for such patients are listed in the text above. (See <a href=\"#H18\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treatment</strong> &mdash; All patients with PRCA and symptomatic anemia should be treated with red cell transfusions as needed for symptomatic anemia, cessation of possible offending drugs (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>), and immediate hematologic consultation. A minority of patients with PRCA will respond to this approach alone.</p><p/><p class=\"bulletIndent1\">The vast majority will have a protracted remitting and relapsing course, requiring long-term support of their anemia with red cell transfusions and long-term treatment with immunosuppressive or cytotoxic agents. Treatment of the underlying condition, if present, may be effective (<a href=\"image.htm?imageKey=HEME%2F57655\" class=\"graphic graphic_table graphicRef57655 \">table 1</a>). (See <a href=\"#H22\" class=\"local\">'Presence of associated conditions'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In addition to red cell transfusions, we suggest that treatment be initiated with glucocorticoids, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, or <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, alone or in combination (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We prefer a graded approach to treatment, starting with glucocorticoids alone, and adding cyclosporine if there is no initial response. (See <a href=\"#H6632060\" class=\"local\">'Initial treatment'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Agents used in patients with resistant or relapsed disease include intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG), <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, antilymphocyte globulin, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, <a href=\"topic.htm?path=alemtuzumab-drug-information\" class=\"drug drug_general\">alemtuzumab</a>, and <a href=\"topic.htm?path=daclizumab-withdrawn-from-market-drug-information\" class=\"drug drug_general\">daclizumab</a>. Hematopoietic cell transplantation may be effective in selected refractory cases. (See <a href=\"#H29\" class=\"local\">'Relapsed and resistant disease'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Treatment of chronic infection and anemia due to parvovirus generally includes the use of red cell transfusions and IVIG, as discussed separately. (See <a href=\"topic.htm?path=treatment-and-prevention-of-parvovirus-b19-infection#H5\" class=\"medical medical_review\">&quot;Treatment and prevention of parvovirus B19 infection&quot;, section on 'Transient aplastic crisis'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-parvovirus-b19-infection#H7\" class=\"medical medical_review\">&quot;Treatment and prevention of parvovirus B19 infection&quot;, section on 'Chronic infection with anemia'</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/1\" class=\"nounderline abstract_t\">Dessypris EN. The biology of pure red cell aplasia. Semin Hematol 1991; 28:275.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/2\" class=\"nounderline abstract_t\">Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/3\" class=\"nounderline abstract_t\">Wang SA, Yue G, Hutchinson L, et al. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion. Br J Haematol 2007; 138:271.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/4\" class=\"nounderline abstract_t\">Inui Y, Yamamoto K, Okamura A, et al. Isolated isochromosome 17q in myelodysplastic syndromes with pure red cell aplasia and basophilia. Intern Med 2012; 51:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/5\" class=\"nounderline abstract_t\">Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol 2006; 135:405.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/6\" class=\"nounderline abstract_t\">Suzuki S, Utsugisawa K, Suzuki N. Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 2013; 84:989.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/7\" class=\"nounderline abstract_t\">Rossert J, Yue S, Smirnakis K, et al. Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agent. Clin Gastroenterol Hepatol 2014; 12:341.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/8\" class=\"nounderline abstract_t\">Korde N, Zhang Y, Loeliger K, et al. Monoclonal gammopathy-associated pure red cell aplasia. Br J Haematol 2016; 173:876.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/9\" class=\"nounderline abstract_t\">Thompson DF, Gales MA. Drug-induced pure red cell aplasia. Pharmacotherapy 1996; 16:1002.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/10\" class=\"nounderline abstract_t\">Bartakke S, Abdelhaleem M, Carcao M. Valproate-induced pure red cell aplasia and megakaryocyte dysplasia. Br J Haematol 2008; 141:133.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/11\" class=\"nounderline abstract_t\">Kurtzman G, Young N. Viruses and bone marrow failure. Baillieres Clin Haematol 1989; 2:51.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/12\" class=\"nounderline abstract_t\">Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87:818.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/13\" class=\"nounderline abstract_t\">Brown KE, Young NS. Parvovirus B19 infection and hematopoiesis. Blood Rev 1995; 9:176.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/14\" class=\"nounderline abstract_t\">Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/15\" class=\"nounderline abstract_t\">Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/16\" class=\"nounderline abstract_t\">al-Awami Y, Sears DA, Carrum G, et al. Pure red cell aplasia associated with hepatitis C infection. Am J Med Sci 1997; 314:113.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/17\" class=\"nounderline abstract_t\">Martins A, Costa A, Oliveira MJ, et al. Pure red cell aplasia due to persistent B19 parvovirus infection in patient infected with human immunodeficiency virus type 1. Recovery with alpha-interferon therapy. Sangre (Barc) 1998; 43:67.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/18\" class=\"nounderline abstract_t\">Davidovitz Y, Halpern Z, Wardi J, et al. Pure red cell aplasia responsive to interferon-alpha in a patient with hepatitis C virus infection. Acta Haematol 1998; 100:213.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/19\" class=\"nounderline abstract_t\">Ramos-Casals M, Garc&iacute;a-Carrasco M, L&oacute;pez-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003; 82:87.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/20\" class=\"nounderline abstract_t\">Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996; 87:4831.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/21\" class=\"nounderline abstract_t\">Clark DA, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 1984; 63:277.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/22\" class=\"nounderline abstract_t\">Baker RI, Manoharan A, de Luca E, Begley CG. Pure red cell aplasia of pregnancy: a distinct clinical entity. Br J Haematol 1993; 85:619.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/23\" class=\"nounderline abstract_t\">Choudry MA, Moffett BK, Laber DA. Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome. Ann Hematol 2007; 86:233.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/24\" class=\"nounderline abstract_t\">Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 2008; 142:505.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/25\" class=\"nounderline abstract_t\">Sawada K, Hirokawa M, Fujishima N, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 2007; 92:1021.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/26\" class=\"nounderline abstract_t\">Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 2008; 93:27.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/27\" class=\"nounderline abstract_t\">Fujiwara T, Yamada M, Miyamura K, et al. Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia. Int J Hematol 2004; 79:293.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/28\" class=\"nounderline abstract_t\">Rabitsch W, Kn&ouml;bl P, Prinz E, et al. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant 2003; 32:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/29\" class=\"nounderline abstract_t\">Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001; 98:1687.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/30\" class=\"nounderline abstract_t\">Verholen F, Stalder M, Helg C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004; 73:441.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/31\" class=\"nounderline abstract_t\">Yang MH, Hsu HC. Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review. Ann Hematol 2001; 80:299.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/32\" class=\"nounderline abstract_t\">Sor&agrave; F, De Matteis S, Piccirillo N, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45:643.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/33\" class=\"nounderline abstract_t\">Aung FM, Lichtiger B, Bassett R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 2013; 160:798.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/34\" class=\"nounderline abstract_t\">Hirokawa M, Fukuda T, Ohashi K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant 2013; 19:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/35\" class=\"nounderline abstract_t\">van der Marel J, Pahlplatz PV, Steup WH, Hendriks ER. Thymoma with paraneoplastic syndromes, Good's syndrome, and pure red cell aplasia. J Thorac Oncol 2007; 2:325.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/36\" class=\"nounderline abstract_t\">Bhargava R, Dolai TK, Singhal D, et al. Pure red cell aplasia associated with thymoma: Is thymectomy the cure? Leuk Res 2009; 33:e17.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/37\" class=\"nounderline abstract_t\">Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/38\" class=\"nounderline abstract_t\">Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013; 56:968.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/39\" class=\"nounderline abstract_t\">Macdougall IC, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 2012; 81:727.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/40\" class=\"nounderline abstract_t\">Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93:1555.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/41\" class=\"nounderline abstract_t\">Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002; 99:1092.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/42\" class=\"nounderline abstract_t\">D'Arena G, Vigliotti ML, Dell'Olio M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol 2009; 82:235.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/43\" class=\"nounderline abstract_t\">Narra K, Borghaei H, Al-Saleem T, et al. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res 2006; 30:109.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/44\" class=\"nounderline abstract_t\">Sawada K, Hirokawa M, Fujishima N. Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am 2009; 23:249.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/45\" class=\"nounderline abstract_t\">Raghavachar A. Pure red cell aplasia: review of treatment and proposal for a treatment strategy. Blut 1990; 61:47.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/46\" class=\"nounderline abstract_t\">Ballester OF, Saba HI, Moscinski LC, et al. Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate. Semin Hematol 1992; 29:106.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/47\" class=\"nounderline abstract_t\">Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001; 97:3995.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/48\" class=\"nounderline abstract_t\">Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114:891.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/49\" class=\"nounderline abstract_t\">Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123:278.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/50\" class=\"nounderline abstract_t\">Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med 2006; 144:181.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/51\" class=\"nounderline abstract_t\">Au WY, Lam CC, Chim CS, et al. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005; 29:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/52\" class=\"nounderline abstract_t\">Abkowitz JL, Powell JS, Nakamura JM, et al. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol 1986; 23:363.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/53\" class=\"nounderline abstract_t\">Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148:791.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/54\" class=\"nounderline abstract_t\">Sloand EM, Olnes MJ, Weinstein B, et al. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica 2010; 95:382.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/55\" class=\"nounderline abstract_t\">Gupta RK, Ezeonyeji AN, Thomas AS, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus 2011; 20:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/56\" class=\"nounderline abstract_t\">Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma 2011; 52:1401.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/57\" class=\"nounderline abstract_t\">Rossignol J, Michallet AS, Oberic L, et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011; 25:473.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/58\" class=\"nounderline abstract_t\">M&uuml;ller BU, Tichelli A, Passweg JR, et al. Successful treatment of refractory acquired pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:1205.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/59\" class=\"nounderline abstract_t\">Palmieri G, Lastoria S, Montella L, et al. Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. Ann Med 1999; 31 Suppl 2:80.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/60\" class=\"nounderline abstract_t\">Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002; 94:1414.</a></li><li><a href=\"https://www.uptodate.com/contents/acquired-pure-red-cell-aplasia-in-the-adult/abstract/61\" class=\"nounderline abstract_t\">Zaucha R, Zaucha JM, Jassem J. Resolution of thymoma-related pure red cell aplasia after octreotide treatment. Acta Oncol 2007; 46:864.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7120 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H30\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ETIOLOGY AND PATHOGENESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Associated disorders</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Erythroid-specific suppression</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Mediators of suppression</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">PRESENTATION</a><ul><li><a href=\"#H280339\" id=\"outline-link-H280339\">Onset of anemia</a></li><li><a href=\"#H6631632\" id=\"outline-link-H6631632\">Clinical findings</a></li><li><a href=\"#H6631639\" id=\"outline-link-H6631639\">Laboratory findings</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">DIAGNOSIS</a></li><li><a href=\"#H2568967\" id=\"outline-link-H2568967\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">PROGNOSIS</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">MANAGEMENT</a><ul><li><a href=\"#H6631738\" id=\"outline-link-H6631738\">Initial management</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Presence of associated conditions</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">Presence of immune-mediated disease</a><ul><li><a href=\"#H6632060\" id=\"outline-link-H6632060\">- Initial treatment</a><ul><li><a href=\"#H6632067\" id=\"outline-link-H6632067\">Addition of cyclosporine</a></li><li><a href=\"#H6632074\" id=\"outline-link-H6632074\">Addition of cyclophosphamide</a></li></ul></li><li><a href=\"#H29\" id=\"outline-link-H29\">- Relapsed and resistant disease</a></li></ul></li></ul></li><li><a href=\"#H30\" id=\"outline-link-H30\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/7120|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/51435\" class=\"graphic graphic_picture\">- Giant proerythroblast in PRCA</a></li></ul></li><li><div id=\"HEME/7120|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/57655\" class=\"graphic graphic_table\">- Causes of acquired pure red cell aplasia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anemia-in-children-due-to-decreased-red-blood-cell-production\" class=\"medical medical_review\">Anemia in children due to decreased red blood cell production</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance\" class=\"medical medical_review\">Clinical course and management of monoclonal gammopathy of undetermined significance</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-parvovirus-b19-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of parvovirus B19 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-myelodysplastic-syndromes\" class=\"medical medical_review\">Clinical manifestations and diagnosis of the myelodysplastic syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-large-granular-lymphocyte-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-management-of-thymoma-and-thymic-carcinoma\" class=\"medical medical_review\">Clinical presentation and management of thymoma and thymic carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">Clinical presentation, pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hemolytic-anemia-in-the-adult\" class=\"medical medical_review\">Diagnosis of hemolytic anemia in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=donor-selection-for-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Donor selection for hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematologic-complications-of-malignancy-anemia-and-bleeding\" class=\"medical medical_review\">Hematologic complications of malignancy: Anemia and bleeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematologic-manifestations-of-rheumatoid-arthritis\" class=\"medical medical_review\">Hematologic manifestations of rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult\" class=\"medical medical_review\">Indications and hemoglobin thresholds for red blood cell transfusion in the adult</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-the-side-effects-of-peginterferon-and-ribavirin-used-for-treatment-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Management of the side effects of peginterferon and ribavirin used for treatment of chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hematopoietic-stem-cells\" class=\"medical medical_review\">Overview of hematopoietic stem cells</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pure-red-cell-aplasia-due-to-anti-erythropoietin-antibodies\" class=\"medical medical_review\">Pure red cell aplasia due to anti-erythropoietin antibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=regulation-of-erythropoiesis\" class=\"medical medical_review\">Regulation of erythropoiesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=smoldering-multiple-myeloma\" class=\"medical medical_review\">Smoldering multiple myeloma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-parvovirus-b19-infection\" class=\"medical medical_review\">Treatment and prevention of parvovirus B19 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-aplastic-anemia-in-adults\" class=\"medical medical_review\">Treatment of aplastic anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-large-granular-lymphocyte-leukemia\" class=\"medical medical_review\">Treatment of large granular lymphocyte leukemia</a></li></ul></div></div>","javascript":null}